Table 3: Efficacy endpoints and stratification characteristics of included trials

Study

Numbei of Eyes

IOP ’ reduction

IOP Preoperative

IOP Postopera-tively

Reduction in medications

Number of Medica-tions Preopera-tively

Number of Medications Postopera-tively

Follow-up (months)

Number of iStents

Combined Phacoe– mulsification

iStent Generation

Type of Glaucoma

Samuelson et al., 2011

117

8.4± 3.6

25.2 ±3.5

n/a

1.4±0.8

1.5 ±0.7

0.2±0.6

12

1

Yes

First

Any

Fea et al., 2014

94

12.2± 2.5

25.2 ±1.4

13.0±2.3

n/a

1.0±0

n/a

12

2

No

Second

Primary

Buchacra et al., 2011

8

6.6±5.4

26.5± 7.9

17.0±2.5

1.1±0.6

2.9±0.7

2

12

1

No

First

Secondary

Ahmed et al., 2014

39

13.5

25.3 ±1.8

11.8±2.1

1.0±0

2.0±0

1.0±0

18

2

No

First

Any

Voskanyan et al., 2014

88

10.4±3.2

26.3± 3.5

15.7±3.7

n/a

2.21±0.44

n/a

12

2

No

Second

Pseudoexfol iative

Vandewalle et al., 2009

9

4.2

20

15.8

1

2.7

1.7

12

1

Mixed

First

Primary

Fea, 2010

12

3.2±3

17.9± 2.6

14.8±1.2

1.6

2±0.9

0.4±0.7

15

1

Yes

First

Primary

Belovay et al., 2012

28

3.5

17.3±4

13.8±4

1.8

2.8±0.8

1.0±1.1

12

2

Yes

First

Primary, mixed

2nd study arm

25

3.9

18.6±4

14.8±3

2.2

2.6±1.2

0.4±0.5

12

3

Yes

First

Primary, mixed

Patel et al., 2013

44

5

21.5 ±5

16.5±3

1.7

2.3±0.9

0.6±1.0

6

1

Mixed

First

Any

Arriola Villalobos et al., 2012

19

3.16±3.9

19.42±1.89

16.26±4.23

0.47±0.96

1.32±0.48

0.84±0.89

Mean: 53.68±9.26

1

Yes

First

Any

Arriola-Villalobos et al., 2013

20

9.42±3

26±3.11

16.75±2.24

1±0.79

1.3±0.66

0.3±0.57

12

1 or 2

Yes

Second

Any open angle

Fernandez-Barrientos et al., 2010

17

6.6±3.0

24.2±1.8

17.6±2.8

1.1

1.1±0.5

0

12

2

Yes

First

Primary

Spiegel et al., 2009

42

4.4±4.54

21.7±3.98

17.4±2.99

1.2±0.7

1.6±0.8

0.4±0.62

12

1

Yes

First

Primary

Wang et al., 2015

96

2.50±5.80

n/a

n/a

1.38±1.43

2.14±0.16

0.76

3

2

Yes

First

Any

Klamann et al., 2015

32

7.67

22.39±1.81

14.72±0.80

1.3

2.26±0.1

0.96±0.11

6

2

No

Second

Primary, pseudoexfol iative, pigmentary

Khan et al., 2015

49

n/a

19.6±5.2

14.3±3.1

n/a

2.86±0.91

1.22±1.28

12

2

Yes

First

Primary, pseudoexfol iative, pigmentary

Seibold et al., 2016

64

1.5

14.7±3.2

13.2±2.8

0.4

1.8±1.1

1.4±1.5

12

1

Yes

First

Any

Gallardo et al., 2016

134

3.6

16.5±3.7

12.9±2.1

1.4

2.3±1.1

0.9±1.2

12

1

Yes

First

Primary

Ferguson et al., 2016

350

4.0

19.1±6.3

15.2±3.5

0.6

1.2±1.0

0.6±1.0

24

1

Yes

First

Primary

Lindstrom et al., 2016

57

10.0

24.4±1.3

14.4±2.1

1.0

1.0±0

0.02

18

2

No

Second

Primary

El Wardani et al., 2015

31

1.6

16.7

15.1

1.7

2.5

0.8

6

1

Yes

First

N/a

2nd Study Arm

22

3.2

17

13.8

1.1

2.1

1

6

2

Yes

First

N/a

Katz et al., 2015

37

10.6

25.0±1.1

14.4 ±1.2

1.6

1.71± 0.61

0.11

12

1

No

First

Primary, pseudoexfol iative, pigmentary

2nd study arm

41

12.2

25.0±1.7

12.8 ±1.4

1.66

1.76±0.54

0.10

12

2

No

First

Primary, pseudoexfol iative, pigmentary

3rd study arm

38

12.9

25.1±1.9

12.2 ±1.5

1.43

1.51± 0.69

0.08

12

3

No

First

Primary, pseudoexfol iative, pigmentary

Shiba et al., 2017

10

5.1

22.0±3.0

16.9 ±3.6

0

3± 0

3±0

6

2

No

First

Primary

Zheng et al., 2017

17

3

19.7±4.1

16.7 ±2.1

1.4

2.2± 1.2

0.8±1.3

6

1

Yes

First

Any

Berdahl et al., 2017

53

6.8

19.7±1.5

12.9 ±2.1

1±0

2± 0

1±0

18

2

No

Second

Any

Ferguson et al., 2017

115

5.49

20.00 ±6.95

14.51 ±2.79

0.7

1.41± 1.04

0.71

24

1

Yes

First

Pseudoexfol iative

Gonnerman n et al., 2017

25

7.8

21.3±4.1

0. 13.5 ±5

0.72

2.0± 0.9

1.28±1.17

12

2

Yes

Second

Primary, pseudoexfol iative

Kurji et al., 2017

34

3.87

17.47 ±4.87

13.6 ±3.4

0.32±0.59

2.15± 1.21

1.83±1.2

6

2

yes

First

Primary, pseudoexfol iative

* IOP = intraocular pressure.